Skip to Content

Sonic Healthcare Ltd SHL

Morningstar Rating
A$26.10 +0.35 (1.36%)
View Full Chart
Unlock our analysis with Morningstar Investor

Company Report

Sonic Healthcare's Long-Term Outlook Remains Strong

Sonic Healthcare’s “medical leadership” model recognizes the importance of the referring doctor as the company seeks to differentiate itself on service levels. Success in the model is evidenced by organic growth consistently tracking ahead of the market, suggesting market share gains. In an industry where absolute volume is an important component in achieving greater cost advantage, organic growth supplemented by appropriate acquisitions continues to add value for shareholders.

Price vs Fair Value

SHL is trading at a 641% premium.
Price
A$26.10
Fair Value
A$68.00
Uncertainty
Medium
1-Star Price
A$98.80
5-Star Price
A$37.40
Economic Moat
Hczvgp
Capital Allocation
Bqttqhmg

Bulls Say, Bears Say

Bulls

Sonic has a leading market position in most of its geographies and as a result benefits from a cost advantage derived from scale.

Bears

Elevated covid-19 testing is not able to be maintained and acquisitive growth is becoming more expensive to achieve.

Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if SHL is a good fit for your portfolio.

News

Trading Information

Previous Close Price
A$25.75
Day Range
A$25.7026.18
52-Week Range
A$23.5836.33
Bid/Ask
A$26.05 / A$26.20
Market Cap
A$12.54 Bil
Volume/Avg
907,879 / 1.7 Mil

Key Statistics

Price/Earnings (Normalized)
24.19
Price/Sales
1.48
Dividend Yield (Trailing)
4.02%
Dividend Yield (Forward)
4.02%
Total Yield
4.02%

Company Profile

Sonic Healthcare is a global pathology provider. It is the largest private operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand, and the third largest in the US. In addition to pathology, which contributes roughly 85% of group revenue, Sonic is the second-largest player in diagnostic imaging in Australia and the largest operator of medical centers in Australia. The company typically earns about 40% of group revenue in Australia and New Zealand, 25% in the US, and 35% in Europe.
Sector
Healthcare
Industry
Diagnostics & Research
Stock Style Box
Large Value
Total Number of Employees
41,000

Competitors

Valuation

Metric
SHL
HLS
LH
Price/Earnings (Normalized)
24.19260.7214.85
Price/Book Value
1.611.012.17
Price/Sales
1.480.521.44
Price/Cash Flow
10.863.1211.61
Price/Earnings
SHL
HLS
LH

Financial Strength

Metric
SHL
HLS
LH
Quick Ratio
0.780.440.58
Current Ratio
0.940.530.88
Interest Coverage
5.95−13.264.03
Quick Ratio
SHL
HLS
LH

Profitability

Metric
SHL
HLS
LH
Return on Assets (Normalized)
4.07%0.10%6.77%
Return on Equity (Normalized)
7.01%0.23%13.92%
Return on Invested Capital (Normalized)
4.52%2.27%8.99%
Return on Assets
SHL
HLS
LH
See how this stock stacks up to its competitors with Morningstar Investor

Diagnostics & Research Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Thermo Fisher Scientific Inc
TMO
XcjynkddfFjbh$206.2 Bil
Danaher Corp
DHR
DhjvjlvxxjWhhtk$177.2 Bil
IDEXX Laboratories Inc
IDXX
RfvzbggtxKzvkxm$40.1 Bil
IQVIA Holdings Inc
IQV
CjmlbqywSybtg$37.9 Bil
Agilent Technologies Inc
A
ZcwcnhqlgKfcy$36.9 Bil
Mettler-Toledo International Inc
MTD
PlnvvpzzmBnhhg$28.7 Bil
Icon PLC
ICLR
ZhrprvpvVwrbk$26.6 Bil
Illumina Inc
ILMN
ZlrzgdqdDcyptd$17.3 Bil
Labcorp Holdings Inc
LH
KkjgxmsdjVbvytyn$17.2 Bil
Waters Corp
WAT
HjhrlvtbzZpkr$17.0 Bil

Sponsor Center